Feng Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Feng Zhu has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Helen Tremlett
Faculty of Medicine (Neurology), and the Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, British Columbia, Canada
7 shared publications - Elaine Kingwell
University of British Columbia
6 shared publications - Ruth Ann Marrie
Department of Medicine, Faculty of Medicine, Dalhousie University, Halifax, NS, Canada
6 shared publications - Charity Evans
College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
5 shared publications - John David Fisk
Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada
4 shared publications - Yinshan Zhao
Faculty of Medicine (Neurology) University of British Columbia and The Djavad Mowafaghian Centre for Brain Health Vancouver British Columbia Canada
4 shared publications
Latest Publications
- Open Access
- 24 March 2026
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 109, 107159
Higher ultra-processed food consumption is associated with higher likelihood of paediatric-onset multiple sclerosis
- 24 March 2026
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 109, 107159
Open AccessHigher ultra-processed food consumption is associated with higher likelihood of paediatric-onset multiple sclerosis
- Open Access
- 14 June 2022
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 9 (5)
Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival
Background and Objectives We examined the association between the disease-modifying drugs (DMDs) for multiple sclerosis (MS) and survival in a multiregion population-based study. Methods We accessed multiple administrative health databases from 4 Canadian provinces. Persons with MS were identified and followed from the most recent of the first MS or demyelinating event or January 1, 1996 (index date), until death, emigration, or December 31, 2017. Association between the first-generation and second-generation DMDs and all-cause mortality was examined using stratified Cox proportional hazard models, reported as adjusted hazard ratios (aHRs). Timing of DMD initiation was explored, with findings reported at 2, 5, or 10 years postindex date, representing very early, early, or late initiation. Results We identified 35,894 persons with MS; 72% were female. The mean age at index date was 44.5 years (SD = 13.6). The total person-years of follow-up while DMD-exposed was 89,180, and total person-years while unexposed was 342,217. Compared with no exposure, exposure to any DMD or to any first-generation DMD was associated with a 26% lower hazard of mortality (both aHRs 0.74; 95% CI 0.56–0.98), while any second-generation DMD exposure was associated with a 33% lower hazard (aHR 0.67; 95% CI 0.46–0.98). Earlier DMD initiation (beta-interferon or glatiramer acetate vs no exposure) was associated with a significant mortality effect (p < 0.05), while later initiation was not (95% CIs included 1). However, the survival advantage with earlier initiation diminished over time, no longer reaching statistical significance at 15 years postindex date. Discussion Our study demonstrates an association between the DMDs for MS and improved survival in the real-world setting.
- 14 June 2022
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 9 (5)
Open AccessDisease-Modifying Drugs for Multiple Sclerosis and Association With Survival
Background and Objectives We examined the association between the disease-modifying drugs (DMDs) for multiple sclerosis (MS) and survival in a multiregion population-based study. Methods We accessed multiple administrative health databases from 4 Canadian provinces. Persons with MS were identified and followed from the most recent of the first MS or demyelinating event or January 1, 1996 (index date), until death, emigration, or December 31, 2017. Association between the first-generation and second-generation DMDs and all-cause mortality was examined using stratified Cox proportional hazard models, reported as adjusted hazard ratios (aHRs). Timing of DMD initiation was explored, with findings reported at 2, 5, or 10 years postindex date, representing very early, early, or late initiation. Results We identified 35,894 persons with MS; 72% were female. The mean age at index date was 44.5 years (SD = 13.6). The total person-years of follow-up while DMD-exposed was 89,180, and total person-years while unexposed was 342,217. Compared with no exposure, exposure to any DMD or to any first-generation DMD was associated with a 26% lower hazard of mortality (both aHRs 0.74; 95% CI 0.56–0.98), while any second-generation DMD exposure was associated with a 33% lower hazard (aHR 0.67; 95% CI 0.46–0.98). Earlier DMD initiation (beta-interferon or glatiramer acetate vs no exposure) was associated with a significant mortality effect (p < 0.05), while later initiation was not (95% CIs included 1). However, the survival advantage with earlier initiation diminished over time, no longer reaching statistical significance at 15 years postindex date. Discussion Our study demonstrates an association between the DMDs for MS and improved survival in the real-world setting.
- Open Access
Accurate classification of secondary progression in multiple sclerosis
Transition from a relapsing-remitting to the secondary progressive phenotype is an important milestone in the clinical evolution of multiple sclerosis. In the absence of reliable imaging or biological markers of phenotype transition, assignment of current phenotype status relies on retrospective evaluation of the medical history of an individual. Here, we sought to determine if demographic and clinical information from multiple sclerosis patients can be used to accurately assign current disease phenotypes: either relapsing-remitting or secondary progressive status. Data from the most recent clinical visit of 14,387 multiple sclerosis patients were extracted from the Swedish Multiple Sclerosis Registry. Decision trees based on sex, symptom onset age, Expanded Disability Scale Status score, and age & disease duration at the most recent clinic visit, were examined to build a classifier to determine disease phenotype. Validation was conducted using an independent cohort of multiple sclerosis patients from British Columbia, Canada, and a previously published classifier to assign phenotype was also tested. Clinical records of 100 randomly selected patients were used to manually categorize phenotype by three independent neurologists. A decision tree (the classifier) containing only most recently available disability score and age obtained 89.3% (95% confidence intervals (CI): 88.8% to 89.8%) classification accuracy, defined as concordance with the latest reported status in the registry. Replication in an independent cohort from British Columbia resulted in 82.0% (95%CI: 81.0% to 83.1%) accuracy. A previously published classification algorithm with slight modifications achieved 77.8% (95%CI: 77.1% to 78.4%) accuracy when assigning disease phenotype. With complete patient history data, three neurologists obtained 84.7% accuracy on average compared with 85 for the classifier using the same data. The model is easily interpretable and could allow research studies and randomized clinical trials to estimate the probability of patients having already reached the secondary progressive stage when they have not yet been retrospectively assigned this status, and to standardize definitions of disease phenotype across different cohorts. Clinically, this model could assist neurologists by providing additional information about the probability of having secondary progressive disease. This could also benefit patients who may be introduced to new therapies targeting progressive multiple sclerosis.
Open AccessAccurate classification of secondary progression in multiple sclerosis
Transition from a relapsing-remitting to the secondary progressive phenotype is an important milestone in the clinical evolution of multiple sclerosis. In the absence of reliable imaging or biological markers of phenotype transition, assignment of current phenotype status relies on retrospective evaluation of the medical history of an individual. Here, we sought to determine if demographic and clinical information from multiple sclerosis patients can be used to accurately assign current disease phenotypes: either relapsing-remitting or secondary progressive status. Data from the most recent clinical visit of 14,387 multiple sclerosis patients were extracted from the Swedish Multiple Sclerosis Registry. Decision trees based on sex, symptom onset age, Expanded Disability Scale Status score, and age & disease duration at the most recent clinic visit, were examined to build a classifier to determine disease phenotype. Validation was conducted using an independent cohort of multiple sclerosis patients from British Columbia, Canada, and a previously published classifier to assign phenotype was also tested. Clinical records of 100 randomly selected patients were used to manually categorize phenotype by three independent neurologists. A decision tree (the classifier) containing only most recently available disability score and age obtained 89.3% (95% confidence intervals (CI): 88.8% to 89.8%) classification accuracy, defined as concordance with the latest reported status in the registry. Replication in an independent cohort from British Columbia resulted in 82.0% (95%CI: 81.0% to 83.1%) accuracy. A previously published classification algorithm with slight modifications achieved 77.8% (95%CI: 77.1% to 78.4%) accuracy when assigning disease phenotype. With complete patient history data, three neurologists obtained 84.7% accuracy on average compared with 85 for the classifier using the same data. The model is easily interpretable and could allow research studies and randomized clinical trials to estimate the probability of patients having already reached the secondary progressive stage when they have not yet been retrospectively assigned this status, and to standardize definitions of disease phenotype across different cohorts. Clinically, this model could assist neurologists by providing additional information about the probability of having secondary progressive disease. This could also benefit patients who may be introduced to new therapies targeting progressive multiple sclerosis.
- 1 October 2019
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 35, 42-49
Higher health care use before a clinically isolated syndrome with or without subsequent MS
- 1 October 2019
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 35, 42-49
Higher health care use before a clinically isolated syndrome with or without subsequent MS
- 1 February 2019
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 28, 138-144
MRI utilization during the diagnostic and post-diagnostic phases in multiple sclerosis
- 1 February 2019
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 28, 138-144
MRI utilization during the diagnostic and post-diagnostic phases in multiple sclerosis
- 1 January 2019
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 27, 364-369
Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: A population-based study
- 1 January 2019
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 27, 364-369
Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: A population-based study
- 1 October 2018
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 25, 258-264
Identifying optic neuritis and transverse myelitis using administrative data
- 1 October 2018
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 25, 258-264
Identifying optic neuritis and transverse myelitis using administrative data